Clinical development of immunotherapies for HER2(+) breast cancer: a review of HER2-directed monoclonal antibodies and beyond

Human epidermal growth factor receptor 2–positive (HER2(+)) breast cancer accounts for ~25% of breast cancer cases. Monoclonal antibodies (mAbs) against HER2 have led to unparalleled clinical benefit for a subset of patients with HER2(+) breast cancer. In this narrative review, we summarize advances...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Ricardo L. B., Czerniecki, Brian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067811/
https://www.ncbi.nlm.nih.gov/pubmed/32195333
http://dx.doi.org/10.1038/s41523-020-0153-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067811/
https://www.ncbi.nlm.nih.gov/pubmed/32195333
http://dx.doi.org/10.1038/s41523-020-0153-3

Ejemplares similares